---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Diagnosis"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Diagnosis. Topics: Establishing the diagnosis: clinical findings and molecular genetic testing, Laboratory testing standards, Clinical motor diagnosis: diagnostic confidence level, Staging: Huntington's Disease Integrated Staging System, and 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/diagnosis"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Establishing the diagnosis: clinical findings and molecular genetic testing

> “The diagnosis of HD is established in a proband with suggestive findings and a heterozygous CAG trinucleotide repeat expansion in HTT identified by molecular genetic testing (see Table 1).”
> “Family history is consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations). Absence of a known family history does not preclude the diagnosis.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state.”

Source: [Stoker et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34413240/)

<a id="topic-2.2.1.5-2"></a>

### Laboratory testing standards

> “Assays used to diagnose Huntington disease must be optimized to ensure the accurate and unambiguous quantitation of CAG repeat length.”

Source: [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)

<a id="topic-2.2.1.5-3"></a>

### Clinical motor diagnosis: diagnostic confidence level

> “Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset.”

Source: [Reilmann et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25164527/)

> “with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15-item motor assessment of the Unified Huntington's Disease Rating Scale)”

Source: [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)

<a id="topic-2.2.1.5-4"></a>

### Staging: Huntington's Disease Integrated Staging System

> “The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

> “If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.”
> “Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.”

Source: [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)

<a id="topic-2.2.1.5-5"></a>

### Predictive genetic testing in at-risk individuals

> “Testing of asymptomatic adults at risk for HD is possible but requires careful deliberation, as there is currently no cure for the disorder”
> “Testing of asymptomatic at-risk adult family members usually involves pretest interviews in which the motives for requesting the test, the individual's knowledge of HD, the possible impact of positive and negative test results, and neurologic status are assessed.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Pre-manifest diagnosis should only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they carry the mutation or not.”

Source: [Roos (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3022767/)

<a id="topic-2.2.1.5-6"></a>

### Biomarkers: plasma neurofilament light protein

> “Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next.”
> “In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036).”

Source: [Byrne et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5507767/)

<a id="topic-2.2.1.5-7"></a>

### Neuroimaging

> “Regional atrophy of the caudate and putamen is among the earliest pathologic changes in HD”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

Additional sources: [MacLeod et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22642570/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
